secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001104659-25-025558
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports FY 2024 net loss of $293M; cash runway into 2027, pipeline milestones ahead
--------------------------------------------------------------------------------

- Net loss $293.0M for FY 2024; cash & equivalents $217.3M at Dec 31, 2024.
- January 2025 upsized offering raised $172.5M gross; cash runway now extends into 2027.
- Phase 3 RINGSIDE topline data for varegacestat in desmoid tumors expected H2 2025.
- Phase 1 of IM-1021 (ROR1 ADC) dosed first patient Feb 2025; IND for IM-3050 (FAP radioligand) submitted March 2025.
- Preclinical ADCs IM-1617, IM-1340, IM-1335 in IND-enabling work; additional discovery programs ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/0001104659-25-025558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer